PDF(1284 KB)
儿童髓母细胞瘤两年内复发危险因素分析
刘晶晶, 孙艳玲, 杜淑旭, 李春德, 龚小军, 李苗, 武万水, 孙黎明
中国当代儿科杂志 ›› 2019, Vol. 21 ›› Issue (8) : 761-765.
PDF(1284 KB)
PDF(1284 KB)
儿童髓母细胞瘤两年内复发危险因素分析
Risk factors for recurrence within 2 years in children with medulloblastoma
目的 探讨儿童髓母细胞瘤（MB）两年内复发的危险因素及对无进展生存（PFS）率的影响。方法 对2017年1~12月收治的123例MB患儿进行回顾性研究，根据复发与否分为复发组（n=30）和非复发组（n=93），分析影响儿童MB两年内复发的危险因素，比较不同因素间的PFS率。结果 大细胞/间变型、M分期，均为儿童MB两年内复发的危险因素。分期为M+者，其复发风险为M0的3.525倍；大细胞/间变型复发风险为经典型的3.358倍，差异有统计学意义（P < 0.05）。生存分析示分期为M+者，中位PFS期为20个月，M+、M0 20个月PFS率分别为50%±11%、81%±5%（P < 0.05）。经典型、促纤维增生/结节型、广泛结节型、大细胞/间变型20个月PFS率分别为80%±5%、65%±10%、86%±13%、36%±20%，不同病理分型之间的PFS率差异有统计学意义（P < 0.05）。结论 复发是影响儿童MB预后的重要因素，分期为M+及大细胞/间变型MB均为复发的危险因素，且PFS率更低。
Objective To investigate the risk factors for recurrence of medulloblastoma (MB) within 2 years and their influence on progression-free survival (PFS). Methods A retrospective analysis was performed for the clinical data of 123 children with MB who were admitted from January to December, 2017. According to the presence or absence of recurrence, they were divided into recurrence group with 30 children and non-recurrence group with 93 children. The risk factors for recurrence within 2 years were analyzed, and PFS was compared between the children with different risk factors. Results Large-cell/anaplastic type and M stage were risk factors for MB recurrence within 2 years. The risk of recurrence in the children with M+ MB was 3.525 times that in those with M0 MB, and the risk of recurrence in the children with large-cell/anaplastic MB was 3.358 times that in those with classic MB (P < 0.05). The survival analysis showed that the median PFS time was 20 months in the children with M+ MB, and the 20-month PFS rate was 50% ±11% in the children with M+ MB and 81% ±5% in those with M0 MB (P < 0.05). The 20-month PFS rate was 80% ±5% in the children with classic MB, 65% ±10% in those with desmoplastic/nodular MB, 86% ±13% in those with MB with extensible nodularity, and 36% ±20% in those with large-cell/anaplastic MB (P < 0.05). Conclusions Recurrence is an important influencing factor for the prognosis of MB, and M+ stage and large-cell/anaplastic MB are risk factors for recurrence. Children with such risk factors tend to have a low PFS rate.
髓母细胞瘤 / M分期 / 病理分型 / 大细胞/间变型 / 儿童
Medulloblastoma / M stage / Pathological type / Large-cell/anaplastic type / Child
[1] Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report:primary brain and central nervous system tumors diagnosed in the United States in 2005-2009[J]. Neuro Oncol, 2012, 14(Suppl 5):v1-v49.
[2] 陈立华, 刘运生, 袁贤瑞, 等. 儿童髓母细胞瘤显微手术治疗[J]. 中国当代儿科杂志, 2002, 4(6):478-481.
[3] Johnston DL, Keene D, Strother D, et al. Survival following tumor recurrence in children with medulloblastoma[J]. J Pediatr Hematol Oncol, 2018, 40(3):e159-e163.
[4] Friedrich C, von Bueren AO, von Hoff K, et al. Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol:a prospective observational multicentre study[J]. Eur J Cancer, 2013, 49(4):893-903.
[5] 廖宇翔, 刘博, 李健, 等. 髓母细胞瘤复发相关因素分析及治疗方式探讨[J]. 国际神经病学神经外科学杂志, 2018, 45(3):234-237.
[6] Koschmann C, Bloom K, Upadhyaya S, et al. Survival after relapse of medulloblastoma[J]. J Pediatr Hematol Oncol, 2016, 38(4):269-273.
[7] Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96):long-term results from a prospective, multicentre trial[J]. Lancet Oncol, 2006, 7(10):813-820.
[8] Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants[J]. J Clin Oncol, 2011, 29(11):1408-1414.
[9] Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas[J]. Radiology, 1969, 93(6):1351-1359.
[10] Tarbell NJ, Friedman H, Polkinghorn WR, et al. High-risk medulloblastoma:a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031)[J]. J Clin Oncol, 2013, 31(23):2936-2941.
[11] Packer RJ, Gajjar A, Vezina G, et al. Phase Ⅲ study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma[J]. J Clin Oncol, 2006, 24(25):4202-4208.
[12] Pizer B, Donachie PH, Robinson K, et al. Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents:results of a Children's Cancer and Leukaemia Group study[J]. Eur J Cancer, 2011, 47(9):1389-1397.
[13] Packer RJ, Zhou T, Holmes E, et al. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy:results of Children's Oncology Group trial A9961[J]. Neuro Oncol, 2013, 15(1):97-103.
[14] Sabel M, Fleischhack G, Tippelt S, et al. Relapse patterns and outcome after relapse in standard risk medulloblastoma:a report from the HIT-SIOP-PNET4 study[J]. J Neurooncol, 2016, 129(3):515-524.
[15] Huang PI, Lin SC, Lee YY, et al. Large cell/anaplastic medulloblastoma is associated with poor prognosis-a retrospective analysis at a single institute[J]. Childs Nerv Syst, 2017, 33(8):1285-1294.
[16] Aref D, Croul S. Medulloblastoma:recurrence and metastasis[J]. CNS Oncol, 2013, 2(4):377-385.
[17] Siegfried A, Bertozzi AI, Bourdeaut F, et al. Clinical, pathological, and molecular data on desmoplastic/nodular medulloblastoma:case studies and a review of the literature[J]. Clin Neuropathol, 2016, 35(3):106-113.
[18] Rutkowski S, von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma:an international meta-analysis[J]. J Clin Oncol, 2010, 28(33):4961-4968.
[19] Khatua S, Song A, Citla Sridhar D, et al. Childhood medulloblastoma:current therapies, emerging molecular landscape and newer therapeutic insights[J]. Curr Neuropharmacol, 2018, 16(7):1045-1058.
[20] Yu J, Zhao R, Shi W, et al. Risk factors for the prognosis of pediatric medulloblastoma:a retrospective analysis of 40 cases[J]. Clinics (Sao Paulo), 2017, 72(5):294-304.
[21] Verlooy J, Mosseri V, Bracard S, et al. Treatment of high risk medulloblastomas in children above the age of 3 years:a SFOP study[J]. Eur J Cancer, 2006, 42(17):3004-3014.
[22] Kortmann RD, Kühl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood:results of the German prospective randomized trial HIT'91[J]. Int J Radiat Oncol Biol Phys, 2000, 46(2):269-279.
[23] Du S, Yang S, Zhao X, et al. Clinical characteristics and outcome of children with relapsed medulloblastoma:a retrospective study at a single center in China[J]. J Pediatr Hematol Oncol, 2018, 40(8):598-604.
[24] Perez-Somarriba M, Andión M, López-Pino MA, et al. Old drugs still work! Oral etoposide in a relapsed medulloblastoma[J]. Childs Nerv Syst, 2019, 35(5):865-869.
